knowledge -WSS

knowledge

author：leisure time 2025-09-07 11:14:38 - browse：59

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Activists slam private health insurers over coverage restrictions
Next article： GSK to buy asthma

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Research misconduct: Proposed new rules face resistance

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

New brain studies show LSD's effects on the brain in full color

leisure time

knowledge

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Medicare proposal to cover medical devices draws a mixed reaction

Caregivers of transplant patients call for more support, training

Medical leaders decry Supreme Court decision on affirmative action

My yearlong odyssey to get my son’s ADHD medication covered

Drug repurposing or repositioning? The language matters

Test for long Covid? Researchers find new clue in blood samples

Bright Health sells Medicare Advantage business to Molina

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

knowledge

FDA clears AI tool for detecting skin cancer

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Eli Lilly, Pfizer, and others want in on the online prescription market

HHS names first

Risky weight loss products often used by teens globally, per study

Parkinson’s finding may lead to tests and, someday, treatments

hotspot

Wikipedia

hotspot

leisure time